Noble Financial reaffirmed their buy rating on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a report issued on Sunday morning.

Several other analysts have also commented on HRTX. BidaskClub lowered shares of Heron Therapeutics from a hold rating to a sell rating in a research note on Friday, August 18th. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the company a buy rating in a research note on Friday, August 18th. Zacks Investment Research raised shares of Heron Therapeutics from a sell rating to a hold rating in a research note on Wednesday, November 8th. Mizuho reissued a buy rating and set a $28.00 target price on shares of Heron Therapeutics in a research note on Tuesday, November 7th. Finally, Jefferies Group LLC reissued a buy rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $28.36.

Shares of Heron Therapeutics (NASDAQ HRTX) traded down $1.00 during trading hours on Friday, hitting $16.35. 2,357,100 shares of the stock were exchanged, compared to its average volume of 817,824. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $20.85. The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The business had revenue of $8.57 million during the quarter, compared to analyst estimates of $8.12 million. equities analysts forecast that Heron Therapeutics will post -3.42 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/13/heron-therapeutics-inc-hrtx-receives-buy-rating-from-noble-financial.html.

Several large investors have recently modified their holdings of HRTX. Janus Henderson Group PLC purchased a new stake in shares of Heron Therapeutics in the 2nd quarter valued at approximately $78,134,000. Vanguard Group Inc. lifted its position in shares of Heron Therapeutics by 40.2% in the 1st quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock valued at $28,127,000 after acquiring an additional 537,563 shares in the last quarter. State Street Corp lifted its position in shares of Heron Therapeutics by 30.7% in the 1st quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock valued at $26,822,000 after acquiring an additional 420,113 shares in the last quarter. Chartwell Investment Partners LLC purchased a new stake in shares of Heron Therapeutics in the 3rd quarter valued at approximately $2,340,000. Finally, Credit Suisse AG lifted its position in shares of Heron Therapeutics by 329.8% in the 1st quarter. Credit Suisse AG now owns 144,061 shares of the biotechnology company’s stock valued at $2,161,000 after acquiring an additional 110,539 shares in the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.